• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Existing evidence is insufficient to justify metformin or other agents as first-line therapy for type 2 diabetes
Commentary on: Palmer SC, Mavridis D, Nicolucci A, et al.. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 2016;316:313–324 . Context A broad consensus supports the use of metformin as first-line therapy for patients with type 2 diabetes. Clinicians and patients, however, may be interested in using newer antihyperglycaemic drugs as first-line treatment, but their relative advantages to metformin—beyond burden of treatment and hypoglycaemic potential—remain uncertain. The systematic review by Palmer et al soug...
Source: Evidence-Based Medicine - November 22, 2016 Category: Internal Medicine Authors: Rodriguez-Gutierrez, R., Montori, V. M. Tags: Epidemiologic studies, Drugs: cardiovascular system, Stroke, Ischaemic heart disease, Diabetes Therapeutics/Prevention Source Type: research

Aspirin reduces cardiovascular events in primary prevention of cardiovascular disease but at a near equivalent risk of increased bleeding
Commentary on: Guirguis-Blake JM, Evans CV, Senger CA, et al.. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the US Preventive Services Task Force. Ann Intern Med 2016;164:804–13 . Context The use of aspirin in primary prevention of cardiovascular disease (CVD) remains controversial, as randomised controlled trials (RCTs) have produced mixed results. Recently, the United States Preventive Services Task Force (USPSTF) published updated recommendations on the use of aspirin for primary prevention of CVD and colorectal cancer.1 This systematic review and meta-analysis serv...
Source: Evidence-Based Medicine - November 22, 2016 Category: Internal Medicine Authors: Miedema, M. D., Virani, S. S. Tags: Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Stroke, Hypertension, Ischaemic heart disease Therapeutics/Prevention Source Type: research

In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates
Commentary on: Lonn EM, Bosch J, López-Jaramillo P, et al.. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016;374:2009–20 . Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016;374:2021–31. Context Cardiovascular diseases (CVD) are the number one cause of death globally: more people die annually from CVDs than from any other cause.1 The incidence of CVD rises progressively with increasing blood pressure (BP) and with increasing levels of total and low density lipoprotei...
Source: Evidence-Based Medicine - November 22, 2016 Category: Internal Medicine Authors: LeFevre, M. Tags: Drugs: cardiovascular system, Pain (neurology), Stroke, Hypertension, Ischaemic heart disease Therapeutics/Prevention Source Type: research

Morphine exposure in preterm infants correlates with impaired cerebellar growth and poorer neurodevelopmental outcome
This study included 136 infants born at 24–32 weeks gestational age who underwent magnetic resonance imaging of the brain near birth and...
Source: Evidence-Based Medicine - November 22, 2016 Category: Internal Medicine Authors: McPherson, C. Tags: Clinical trials (epidemiology), Epidemiologic studies, Pain (neurology), Stroke, Pain (palliative care), Radiology, Drugs: musculoskeletal and joint diseases, Clinical diagnostic tests, Radiology (diagnostics) Aetiology/Harm Source Type: research

Cognitive adverse effects and brain deterioration associated with use of anticholinergic activity medicines in older adults
This study examined whether medicines with anticholinergic activity alter brain glucose metabolism, and the impact this has on brain structure, function and cognitive decline. Methods This retrospective cohort study involved 402 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) centre and 49 participants from the Indiana Memory and Aging Study (IMAS). Data on cognitive and neuroimaging findings...
Source: Evidence-Based Medicine - November 22, 2016 Category: Internal Medicine Authors: Nishtala, P. S., Salahudeen, M. S. Tags: Geriatric medicine, Epidemiologic studies, Dementia, Drugs: CNS (not psychiatric), Sleep disorders (neurology), Stroke, Memory disorders (psychiatry), Psychiatry of old age, Sleep disorders, Sleep disorders (respiratory medicine) Aetiology/Harm Source Type: research

Decompressive craniectomy for severe traumatic brain injury reduces mortality but increases survival with severe disability
Commentary on: Hutchinson PJ, Kolias AG, Timofeev IS, et al.. Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension. N Engl J Med 2016;375:1119–30. Context There is little doubt that decompressive craniectomy can reduce mortality in traumatic brain injury; this was clearly demonstrated by previous trials investigating the efficacy of decompressive hemicraniectomy following ischaemic stroke.1 However, surgical decompression will not reverse the effects of the pathology that precipitated the neurological crisis and the concern has always been that the reduction in mortality comes at the cost of an ...
Source: Evidence-Based Medicine - March 23, 2017 Category: Internal Medicine Authors: Honeybul, S. Tags: Therapeutics/Prevention Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11